Abstract
BackgroundLocally advanced prostate cancer (LACAP), despite external beam radiotherapy (EBRT) along with antiandrogen therapy (ADT) has risk of prostate-specific antigen (PSA) progression. Furthermore, number of studies have emphasized on different prognostic factors. The purpose of our study is to analyze risk factors for biochemical failure (BF) in these patients treated at our institute.MethodsOur study is a single-institution retrospective observational done at a tertiary care center in North India. Between January 2018 and December 2020, we retrospectively identified 34 patients managed at our institute as per multidisciplinary board (MBD). Demographic, clinical, radiological, pathological and treatment-related parameters were assessed as potential risk factors. End-point of the study was to find significant risk factors for BF. Statistical analysis was done on SPSS, version 20 (IBM Corp., Armonk, NY).ResultsAll eligible patients received EBRT with ADT as per institution policy. Mean follow-up period was 20 months during which two (5.9%) patients had BF at a mean of 30 months after EBRT. Four-year PSA-progression-free survival rate was 73%. On univariate analysis, prognostic factors associated with high risk of BF were Gleason score and clinical T stage.ConclusionIn summary, prognostic factors for high risk of BF leading to clinical progression are Gleason score 9 or 10 and clinical T3b stage.
Highlights
In India annual prostate cancer incidence rate ranges from 5.0 to 9.1 per 100,000/year [1], and of all, 85% are detected late
Prognostic factors associated with high risk of biochemical failure (BF) were Gleason score and clinical T stage
We retrospectively analyzed prognostic factors precisely leading to BF in our group of locally advanced prostate cancer (LACAP) prostate treated with standard external beam radiotherapy (EBRT) and antiandrogen therapy (ADT)
Summary
In India annual prostate cancer incidence rate ranges from 5.0 to 9.1 per 100,000/year [1], and of all, 85% are detected late (stages III and IV). Recommended treatment for locally advanced prostate cancer is external beam radiotherapy (EBRT) and antiandrogen therapy (ADT) as supported by the literature [2,3,4]. It is important to note that the rise of prostate-specific antigen (PSA) above a defined threshold, which is called biochemical failure (BF), is usually the earliest harbinger of replaced disease after radiotherapy, and may manifest years prior to clinical recurrence [7]. We retrospectively analyzed prognostic factors precisely leading to BF in our group of locally advanced prostate cancer (LACAP) prostate treated with standard EBRT and ADT. Advanced prostate cancer (LACAP), despite external beam radiotherapy (EBRT) along with antiandrogen therapy (ADT) has risk of prostate-specific antigen (PSA) progression.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
